logo

Miguel Villalona, MD

Miguel Villalona, MD

Oncology Columbus, OH

Physician

Office Address

Office Map
  • 300 W 10th Ave
    Columbus, OH 43210
    Phone: (614) 293-8619
    Fax: (614) 293-6420

Dr. Villalona's Clinical Specialties & Interests

  • Oncology: General Oncology

Dr. Villalona's Education & Medical Training

  • University of Texas Health Science Center at San AntonioUniversity of Texas Health Science Center at San AntonioFellowship, Medical Oncology
  • Roswell Park Cancer InstituteRoswell Park Cancer InstituteFellowship, Medical Oncology
  • University of Minnesota at FairviewUniversity of Minnesota at FairviewFellowship, Medical Oncology
  • SUNY Health Science Center at BrooklynSUNY Health Science Center at BrooklynResidency, Internal Medicine
  • Universidad Nacional Pedro Henriquez UrenaUniversidad Nacional Pedro Henriquez UrenaMedical School

Dr. Villalona's Certifications & Licensure

  • OH State Medical LicenseOH State Medical License1999 - 2015
  • innactiveinnactiveFL,Active through 2013
  • American Board of Internal MedicineAmerican Board of Internal MedicineInternal Medicine
  • American Board of Internal MedicineAmerican Board of Internal MedicineMedical Oncology

Dr. Villalona's Awards, Honors, & Recognition

  • Centers for Medicare & Medicaid ServicesMeaningful Use Stage 1 CertificationCenters for Medicare & Medicaid Services, 2012
  • American Association for the Advancement of ScienceFellowAmerican Association for the Advancement of Science
  • American College of PhysiciansFellowAmerican College of Physicians
  • Register to See 1 More...

Dr. Villalona's Publications & Presentations

PubMed | Citations by Web of Science®

Grant Support

  • Early Therapeutics Development With Phase II Emphasis
    Early Therapeutics Development With Phase II EmphasisNational Cancer Institute
    2011 - 2011
  • Targeting Somatic Homologous Recombination In Solid Tumors
    Targeting Somatic Homologous Recombination In Solid TumorsNational Cancer Institute
    2010 - 2012
  • Early Therapeutics Development With Phase II Emphasis
    Early Therapeutics Development With Phase II EmphasisNational Cancer Institute
    2010 - 2010
  • Tas:: 75 0850 ::Tas Recovery ACT - Actnow Clinical Trial 8472
    Tas:: 75 0850 ::Tas Recovery ACT - Actnow Clinical Trial 8472Division Of Cancer Treatment
    2009 - 2009
  • Early Therapeutics Development With Phase II Emphasis
    Early Therapeutics Development With Phase II EmphasisDivision Of Cancer Treatment
    2009 - 2009
  • Biomodulation Of Capecitabine By Docetaxel In Non-Small*
    Biomodulation Of Capecitabine By Docetaxel In Non-Small*National Cancer Institute
    2004 - 2005
  • TNF Blockade In Pancreatic Cancer Patients
    TNF Blockade In Pancreatic Cancer PatientsNational Cancer Institute
    2003 - 2004
  • Phase II Randomized Trial Of CPT-11 And Mitomycin C
    Phase II Randomized Trial Of CPT-11 And Mitomycin CNational Cancer Institute
    2002 - 2003
  • Phase I Study Of Sequential CPT 11 &Mitomycin C
    Phase I Study Of Sequential CPT 11 &Mitomycin CNational Center For Research Resources
    1999 - 2002
  • Translational Research In Lung Cancer
    Translational Research In Lung CancerNational Cancer Institute
    1998 - 2002
  • Phase I Protocol To Determine The Safety Of Lu79553 As An IV Infusion Daily X 5
    Phase I Protocol To Determine The Safety Of Lu79553 As An IV Infusion Daily X 5National Center For Research Resources
    1998 - 1999
  • Phase I Trial Of PN401 As Rescue Agent For Escalating Doses Of 5-FU
    Phase I Trial Of PN401 As Rescue Agent For Escalating Doses Of 5-FUNational Center For Research Resources
    1997 - 1999
  • Phase I Study To Determine The Safety Of Ecteinascidin-743
    Phase I Study To Determine The Safety Of Ecteinascidin-743National Center For Research Resources
    1997 - 2000
  • Phase I Protocolto Determine The Safety Of Lu79553 As An IV Infusion Daily X 5
    Phase I Protocolto Determine The Safety Of Lu79553 As An IV Infusion Daily X 5National Center For Research Resources
    1997 - 1997
  • Translational Research In Lung Cancer
    Translational Research In Lung CancerNational Cancer Institute
    1997 - 1998
  • Effect Of H Corticotropin Releasing Factor On Peritumoral Brain
    Effect Of H Corticotropin Releasing Factor On Peritumoral BrainNational Center For Research Resources
    1996 - 1996

Other Languages

  • Spanish

Insurance Accepted

  • Aetna Choice POS II
  • Aetna HMO
  • Anthem Blue Access PPO
  • Anthem Blue Preferred HMO
  • BCBS Blue Card PPO
  • BCBS Illinois PPO
  • CIGNA HMO
  • CIGNA Open Access
  • CIGNA PPO
  • Cofinity PPO
  • First Health PPO
  • Great West PPO
  • HealthAmerica HealthAssurance PPO
  • Humana ChoiceCare Network PPO
  • Medical Mutual of Ohio SuperMed Plus
  • Medical Mutual of Ohio SuperMed POS
  • Multiplan PHCS PPO
  • Multiplan PPO
  • United Healthcare - Direct Choice Plus POS
  • United Healthcare - Direct Options PPO

Physicians, view Dr. Villalona's full Doximity profile to:

  • Trade HIPAA-secure messages
  • Send and receive online faxes
  • Refer a patient
  • See their complete CV